Neuromuscular Agents
Research News and Information

Monday, November 23, 2009

Botulinum toxin type A in the healing of a chronic buttock ulcer in a patient with spastic paraplegia after spinal cord injury.

30 Oct 2009 BACKGROUND: Pressure sores are a significant secondary complication in spinal cord injured patients. A new indication for botulinum toxin type A is described here, in treatment of recurrent muscular spasms that had hampered the healing of a chronic ... Read more...

When drugs disappear from the patient: elimination of intravenous medication by hemodiafiltration.

30 Oct 2009 Twenty-three hours after heart transplantation, life-threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration (CVVHDF). Increasing doses of catecholamines, sedatives, and muscle relaxants ... Read more...

Robot-mediated and clinical scales evaluation after upper limb botulinum toxin type A injection in children with hemiplegia.

30 Oct 2009 OBJECTIVE: The aim of this pilot study was to examine changes in different aspects of impairment, including spasticity in the upper limbs, of hemiplegic children following botulinum toxin type A intervention. Progress was assessed using standard ... Read more...

Latest indexed articles for 'Neuromuscular Agents'

These are the very latest articles for this heading:

• Botulinum toxin type A in the healing of a chronic buttock ulcer in a patient with spastic paraplegia after spinal cord injury. 30 Oct 2009
• When drugs disappear from the patient: elimination of intravenous medication by hemodiafiltration. 30 Oct 2009
• Robot-mediated and clinical scales evaluation after upper limb botulinum toxin type A injection in children with hemiplegia. 30 Oct 2009
• The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhydrosis with botulinum toxin injections. 29 Sep 2009
• A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. 29 Sep 2009
• Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia. 29 Sep 2009
• Effectiveness of sedation using nitrous oxide compared with enteral midazolam for botulinum toxin A injections in children. 29 Sep 2009
• [Therapeutic modalities in the treatment of palmar and axillary hyperhidrosis] 18 Sep 2009
• The use of botulinum type A toxin in the treatment of idiopathic clubfoot: 5-year follow-up. 30 Aug 2009
• The effectiveness of botulinum A toxin as an adjunct to the treatment of clubfeet by the Ponseti method: a randomized, double blind, placebo controlled study. 30 Aug 2009
• Treatment of severe achalasia during pregnancy with esophagoscopic injection of botulinum toxin A: a case report. 30 Aug 2009
• Medical treatment for pregnant women: balancing risks and benefits. 30 Aug 2009
• Letter to the editor on 'Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials'. 30 Aug 2009
• I have an anal fissure that isn't getting better even though I've increased my fiber and water intake over past few months. My doctor is recommending surgery to cut part of the anal sphincter. Are there any other treatment options? 30 Aug 2009
• Differences in botulinum toxins: time to end the confusion. 30 Aug 2009
• Botulinum toxin in aesthetic applications: 'how often misused words generate misleading thoughts'. (Response to: De Boulle K. Patient satisfaction with different botulinum toxin type A formulations in the treatment of moderate to severe upper facial rhytids. J Cosmet Laser Ther. 2008;10:87-92). 30 Aug 2009
• Treatment of hyperkinetic movement disorders. 30 Aug 2009
• Effect of baseline spastic hemiparesis on recovery of upper-limb function following botulinum toxin type A injections and postinjection therapy. 30 Aug 2009
• A preliminary assessment of the benefits of the addition of botulinum toxin a to a conventional therapy program on the function of people with longstanding stroke. 30 Aug 2009
• Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review). 30 Aug 2009

See a longer list of these articles.

Technical information about 'Neuromuscular Agents'

Definition: Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.

Registry Number: 0

Descriptor UI: D009465

Alternative terms: Neuromuscular Agents; Agents, Neuromuscular; Skeletal Muscle Relaxants; Muscle Relaxants, Skeletal; Relaxants, Skeletal Muscle;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.696.663.700;

Online Note: use MUSCLE RELAXANTS, CENTRAL to search SKELETAL MUSCLE RELAXANTS 1977-94

History Note: 95; was NON MESH 1974-94; SKELETAL MUSCLE RELAXANTS was see MUSCLE RELAXANTS, CENTRAL 1977-94

Technical Notes: GEN or unspecified; prefer specifics; consider also NEUROMUSCULAR JUNCTION /drug eff & MUSCLES, SKELETAL /drug eff